Quarterly report pursuant to Section 13 or 15(d)

Operating Segments (Tables)

Operating Segments (Tables)

6 Months Ended

Jun. 30, 2023

Schedule of Segment Reporting Information

The table below presents certain financial information of our operating segments for the three and six months ended June 30, 2023 and 2022 (in thousands):

Segment Reporting for the Quarter Ended June 30, 2023

										⁽¹⁾
	Treatment			Services		Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	12,834		$	12,198	$	25,032		$	—		$	25,032
Intercompany revenues		26			17		43			—			—
Gross profit		2,491			2,025		4,516			—			4,516
Research and development		91			7		98			23			121
Interest income		—			—		—			172			172
Interest expense		(23	)		—		(23	)		(24	)		(47	)
Interest expense-financing fees		—			—		—			(24	)		(24	)
Depreciation and amortization		589			89		678			14			692
Segment income (loss) before income taxes		1,356			1,189		2,545			(1,594	)		951
Income tax expense		83			349		432			—			432
Segment income (loss)		1,273			840		2,113			(1,594	)		519
Expenditures for segment assets		293			5		298			—			298	⁽²⁾

Segment Reporting for the Six Months Ended June 30, 2023

											⁽¹⁾
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	22,428		$	22,711		$	45,139		$	—		$	45,139
Intercompany revenues		230			36			266			—			—
Gross profit		3,743			3,782			7,525			—			7,525
Research and development		158			10			168			52			220
Interest income		—			—			—			298			298
Interest expense		(45	)		(1	)		(46	)		(54	)		(100	)
Interest expense-financing fees		—			—			—			(44	)		(44	)
Depreciation and amortization		1,162			249			1,411			28			1,439
Segment income (loss) before income taxes		1,514			2,132			3,646			(3,216	)		430
Income tax (benefit) expense		(91	)		319			228			—			228
Segment income (loss)		1,605			1,813			3,418			(3,216	)		202
Expenditures for segment assets		1,043			4			1,047			—			1,047	⁽²⁾

Segment Reporting for the Quarter Ended June 30, 2022

										⁽¹⁾
	Treatment			Services		Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	8,393		$	11,062	$	19,455		$	—		$	19,455
Intercompany revenues		—			17		17			—			—
Gross profit		1,563			1,321		2,884			—			2,884
Research and development		59			8		67			13			80
Interest income		—			—		—			29			29
Interest expense		(19	)		3		(16	)		(25	)		(41	)
Interest expense-financing fees		—			—		—			(15	)		(15	)
Depreciation and amortization		381			86		467			13			480
Segment income (loss) before income taxes		364			515		879			(1,789	)		(910	)
Income tax expense		304			43		347			—			347
Segment income (loss)		60			472		532			(1,789	)		(1,257	)
Expenditures for segment assets		373			39		412			—			412	⁽³⁾

Segment Reporting for the Six Months Ended June 30, 2022

											⁽¹⁾
	Treatment			Services			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	15,872		$	19,498		$	35,370		$	—		$	35,370
Intercompany revenues		—			27			27			—			—
Gross profit		2,201			2,319			4,520			—			4,520
Research and development		124			23			147			29			176
Interest income		—			—			—			40			40
Interest expense		(33	)		2			(31	)		(45	)		(76	)
Interest expense-financing fees		—			—			—			(28	)		(28	)
Depreciation and amortization		752			157			909			27			936
Segment (loss) income before income taxes		(117	)		799			682			(3,514	)		(2,832	)
Income tax benefit		(254	)		(72	)		(326	)		—			(326	)
Segment income (loss)		137			871			1,008			(3,514	)		(2,506	)
Expenditures for segment assets		670			88			758			—			758	⁽³⁾

⁽¹⁾	Amounts reflect the activity for corporate headquarters not included in the segment information.

⁽²⁾	Net of financed amount of $107,000 and $157,000 for the three and six months ended June 30, 2023, respectively.

⁽³⁾	Net of financed amount of $0 and $114,000 for the three and six months ended June 30, 2022, respectively.